News
Releases

Dr. Schayowitz brings nearly 20 years of oncology drug development experience, including development leadership roles at Pfizer Oncology and Tesaro Dr. Schayowitz has led dozens of global development programs and led multiple registration programs through regulatory approval AUSTIN, Texas

In two preclinical breast cancer xenograft models (abstract #431P), PIKTOR inhibited tumor growth to a comparable or greater extent than intravenous gedatolisib PIKTOR inhibited HR+/HER2- breast cancer xenograft tumor growth in models with and without a PIK3CA mutation, the same population

AUSTIN, Texas --(BUSINESS WIRE)--Oct. 22, 2026-- Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted three new employees options to purchase an aggregate of 17,000 shares of the Company’s common stock in connection with their

Poster will characterize the efficacy of PIKTOR as a monotherapy and in combination with fulvestrant, oral SERDs, and CDK inhibitors in preclinical models of breast cancer Poster also includes results from head-to-head comparisons with gedatolisib, another multi-nodal inhibitor of the PI3K-AKT-mTOR

Renowned cancer biologist and Faeth scientific co-founder joins the Board as the Company approaches topline Phase 2 data for PIKTOR in endometrial cancer AUSTIN, Texas --(BUSINESS WIRE)--Sep. 17, 2026-- Faeth Therapeutics, Inc. (Nasdaq: FTH), a clinical-stage biotechnology company focused on

AUSTIN, Texas --(BUSINESS WIRE)--Sep. 8, 2026-- Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, October

AUSTIN, Texas --(BUSINESS WIRE)--Sep. 1, 2026-- Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that management will participate in the following upcoming investor

AUSTIN, Texas --(BUSINESS WIRE)--Aug. 28, 2026-- Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted three new employees options to purchase an aggregate of 94,000 shares of the Company’s common stock in connection with their

— Fast Track designation applies to sapanisertib and serabelisib (PIKTOR) in combination with paclitaxel for the treatment of patients with advanced or recurrent endometrial cancer whose tumors harbor a PI3K/AKT/mTOR pathway alteration — Faeth expects topline data from its ongoing Phase 2 trial in

Appointments reinforce technical operations and investor engagement as the company advances its clinical programs AUSTIN, Texas --(BUSINESS WIRE)--Aug. 14, 2026-- Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced the appointments of Deepak Tiwari as Senior Vice President, Technical Operations,